

References

E-58

1. Francis J, Reek S. Wearable cardioverter defibrillator: A life vest till the life boat (ICD) arrives. *Indian Heart Journal*. 2014;66(1):68-72.
2. Wan C, Herzog C, Zareba W, et al. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. *Annals of Noninvasive Electrocardiology*. 2014;19(3):247-257.
3. Chung M. The role of the wearable cardioverter defibrillator in clinical practice. *Cardiology Clinic*. 2014;32(2):253-70.
4. Chung M. Wearable cardioverter-defibrillator. *UpToDate*. 2014.
5. Deeprasertkul P, Opreanu M, Bianco N, et al. National experience with wearable cardioverter-defibrillator use in takotsubo cardiomyopathy. *The Journal of Innovations in Cardiac Rhythm Management*. 2014;5:1707-1713.
6. Jancin B. Wearable defibrillator impresses as bridge. *American College of Emergency Physicians*. 2014.
7. Kondo Y, Linhart M, Andrie RP, et al. Usefulness of the wearable cardioverter defibrillator in patients in the early post-myocardial infarction phase with high risk of sudden cardiac death: A single-center European experience. *APHRS JHRS*. 2015;292-295.
8. Tananwuttiwat T, Garisto JD, Salow A, et al. Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator. *PACE*. 2014;562-568.
9. Duncker D, Haghikia A, Konig T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator. *Eur Heart J*. 2014;1331-1336.
10. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. *JACC*. 2014;1143-1177.
11. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. *Eur Heart J*. 2015.
12. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). *Circulation*. 2015;132(17):1613-1619.
13. Lamichhane M, Safadi A, Surapaneni P, et al. Use of the wearable cardioverter defibrillator in high-risk populations. *Curr Cardiol Rep*. 2016;18(8):1-8.
14. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. *Circulation*. 2014;130(1):94-125.
15. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130(25):e344-426.

16. Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, et al. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. *Circulation*. 2016;133:1715-1727.
17. Duncker D, Thorben K, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation. *J Am Heart Assoc*. 2017;6:e004512.
18. Reek S, Burri H, Roberts PR, Perings C, Epstein AE, et al. The wearable cardioverter-defibrillator: current technology and evolving indications. *Europace*. 2017;19: 335–345.
19. Uyei J, Braithwaite RS. Effectiveness of wearable defibrillators: Systematic review and quality of evidence. *Int J Technol Assess Health Care*. 2014;30(2):194-202.
20. Gaspar HA, Morhy SS. The role of focused echocardiography in pediatric intensive care: A critical appraisal. *Biomed Res Int*. 2015;doi:10.1155/2015/596451.
21. Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis. *J Heart Lung Transplant*. 2015;34(10):1305-1309.
22. Jayaprasad N. Heart failure in children. *Heart Views*. 2016;17(3):92-99.
23. Salehi N, Nasiri M, Bianco NR, Opreanu M, Singh V, et al. The wearable cardioverter defibrillator in non-ischemic cardiomyopathy: A US national database analysis. *Can J Cardiol*. 2016;32(10):1247 e1241-1247.
24. Wässnig NK, Gunther M, Quick S, Pfluecke C, Rottstadt F, et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. *Circulation*. 2016;134(9):635-643.
25. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Ventricular arrhythmias in patients with newly diagnosed non-ischemic cardiomyopathy: Insights from the PROLONG study. *Clin Cardiol*. 2017;40(8):586-590.
26. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-The PROLONG Study. *J Am Heart Assoc*. 2017;6(1).
27. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2018;138(13).
28. Spar DS, Bianco NR, Knilans TK, et al. The US experience of the wearable cardioverter-defibrillator in pediatric patients. *Circ Arrhythm Electrophysiol*. 2018;11:e006163.